Research programme: Lewis Y antigen-targeted cancer antibody - Meridian BiopharmaceuticalsAlternative Names: Glyco-modified optimised antibody; MB 314
Latest Information Update: 05 Jun 2015
At a glance
- Originator Meridian Biopharmaceuticals
- Class Monoclonal antibodies
- Mechanism of Action Lewis Y antigen modulators
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
On Fast track
Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.
- New Molecular Entity Yes
Highest Development Phases
- Preclinical Cancer
Most Recent Events
- 05 Jun 2015 Preclinical trials in Cancer in Austria (Parenteral) (Meridian Biotech website, June 2015)